OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

MERCK KGAA O.N./  DE0006599905  /

TradeGate
9/29/2023  8:00:03 AM Chg. -0.150 Volume Bid8:01:08 AM Ask8:01:08 AM Market Capitalization Dividend Y. P/E Ratio
156.750EUR -0.10% 12
Turnover: 1,881		 155.400Bid Size: 77 156.800Ask Size: 100 20.17 bill.EUR 1.41% 20.40
TeleTrader 8/29 US gov't reveals drugs subject to Medicare price debate
TeleTrader 8/1 Merck posts Q2 sales of $15B, rising 3%
TeleTrader 6/6 WH defends Medicare over Merck lawsuit
TeleTrader 6/6 Merck sues US gov't over drug price negotiations
TeleTrader 5/8 Merck appoints Helene von Roeder as new CFO
TeleTrader 4/27 Merck's Q1 sales land at $14.5B, down 9%
TeleTrader 4/16 Merck reportedly in talks to buy Prometheus Biosciences
TeleTrader 2/24 EU regulator recommends against Merck's COVID drug
TeleTrader 2/2 Merck posts Q4 sales up 2% to $13.8B
TeleTrader 1/13 J&J reportedly cuts COVID vaccine production
TeleTrader 12/30/2022 China greenlights import of Merck's COVID pill
TeleTrader 12/13/2022 Moderna soars 22% on cancer vaccine breakthrough
TeleTrader 12/13/2022 Moderna soars 8% premarket on cancer vaccine results
TeleTrader 12/12/2022 Merck starts tender offer for Imago BioSciences at $36 per share
TeleTrader 10/27/2022 Merck: Q3 sales increase 14% to $14.96B
TeleTrader 7/28/2022 Merck: EPS more than triples to $1.55 in Q2
TeleTrader 6/24/2022 Merck advances in talks to acquire Seagen - report
TeleTrader 6/17/2022 Merck discussing buying Seagen for $28B - report
TeleTrader 4/28/2022 Merck's Q1 EPS up 57% to $1.70
TeleTrader 3/16/2022 Merck halts new Russia investments
TeleTrader 2/17/2022 South Africa authorizes Merck's COVID drug
GlobeNewswire 2/10/2022 Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Cl...
TeleTrader 2/3/2022 Merck's sales up by 24% to $13.52 billion in Q4
TeleTrader 1/18/2022 Merck, Ridgeback to supply 3 million courses of molnupiravir
GlobeNewswire 1/11/2022 Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH